BioSniper
Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Randomized, Double-blind, Active-Controlled, Parallel, Phase Ⅲ Study to Evaluate the

October 1, 2028
Company
NYMOX PHARMACEUTICAL CORP (NYMXF)
Indication
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia

Other upcoming events for NYMXF

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua
Oct 29, 2026
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Effic
Dec 30, 2026
Patent ExpiryPatent/Exclusivity Expiry: SIRTURO
May 27, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy an
Jun 30, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the
Jan 31, 2028

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
NYMXF OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle